🤧 Decongestant & Antihistamine Symptom Relief Simulator

Nasal Mucosa Swelling During a Cold

Viral infection dilates nasal blood vessels, causing tissue swelling and blockage.

• 2-3x: Mucosal thickness (placeholder baseline swelling)
• ~60%: Airflow reduction (placeholder obstruction estimate)
• elevated: Histamine release (placeholder inflammatory signal)
• dilated: Vessel state (placeholder vascular tone)

Why the nose swells shut

Inflammation dilates vessels and leaks fluid into nasal tissue.

Placeholder: baseline swelling sets the stage for treatment.

Pseudoephedrine and Alpha-1 Receptors

Pseudoephedrine stimulates alpha-1 receptors to constrict nasal vessels.

• alpha-1: Receptor target (placeholder adrenergic subtype)
• ~30 min: Onset time (placeholder pharmacokinetics)
• -40%: Vessel diameter (placeholder constriction effect)
• 4-6 hrs: Duration (placeholder dosing interval)

How constriction happens

Placeholder: sympathomimetic action shrinks swollen vessels.

Placeholder: dose-dependent vasoconstriction reduces swelling.

Reopening the Nasal Passage

Shrunken vessels free space for air to pass through the nose again.

• restored: Lumen area (placeholder airway opening)
• +50%: Airflow gain (placeholder improvement estimate)
• lowered: Congestion score (placeholder symptom metric)
• overuse: Rebound risk (placeholder rhinitis medicamentosa note)

Airway patency improves

Placeholder: decongestion restores comfortable breathing.

Placeholder: patency rises as vessel volume drops.

Antihistamines Block Histamine Signaling

Antihistamines occupy H1 receptors, preventing histamine from triggering sneezing.

• H1: Receptor target (placeholder receptor subtype)
• reduced: Sneeze reflex (placeholder neural signal)
• lowered: Itching score (placeholder symptom metric)
• 1st-gen only: Sedation risk (placeholder side-effect note)

Competitive receptor blockade

Placeholder: antihistamines compete with histamine for H1 sites.

Placeholder: blocking H1 cuts sneezing and itch signals.

Decongestant Plus Antihistamine Together

Combining both drug classes relieves congestion, sneezing, and itching together.

• minimal: Congestion (placeholder combined outcome)
• minimal: Sneezing (placeholder combined outcome)
• high: Patency (placeholder combined outcome)
• maximal: Overall relief (placeholder combined outcome)

Synergy of combination therapy

Placeholder: combined mechanisms treat multiple cold symptoms.

Placeholder: dual therapy covers congestion and allergic signaling.